https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-27 / Cancers (Basel) 2020 Feb;12(3)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-27 / Cancers (Basel) 2020 Feb;12(3)2020-02-27 00:00:002020-02-27 00:00:00Photodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-26 / J Cell Mol Med 2020 04;24(7):4286-4297
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-26 / J Cell Mol Med 2020 04;24(7):4286-42972020-02-26 00:00:002022-09-29 14:03:50Targeting STAT3 enhances NDV-induced immunogenic cell death in prostate cancer cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-22 / Cancer Immunol. Immunother. 2020 Jun;69(6):1015-1027
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-22 / Cancer Immunol. Immunother. 2020 Jun;69(6):1015-10272020-02-22 00:00:002020-08-26 14:19:05Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-21 / Magy Onkol 2021 Mar;65(1):71-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-21 / Magy Onkol 2021 Mar;65(1):71-772020-02-21 00:00:002020-02-21 00:00:00[The adjuvant killing effect of modulated electro-hyperthermia combined with chemotherapy on B16F10 melanoma cells]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-21 / Front Oncol 2020;10:187
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-21 / Front Oncol 2020;10:1872020-02-21 00:00:002020-02-21 00:00:00Immunotherapy in Malignant Pleural Mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-20 / Cancer Immunol. Immunother. 2020 Jul;69(7):1375-1387
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-20 / Cancer Immunol. Immunother. 2020 Jul;69(7):1375-13872020-02-20 00:00:002020-02-20 00:00:00Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-09 / Neoplasma 2020 May;67(3):677-683
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-09 / Neoplasma 2020 May;67(3):677-6832020-02-09 00:00:002020-02-09 00:00:00Feasibility of modulated electro-hyperthermia in preoperative treatment for locally advanced rectal cancer: Early phase 2 clinical results
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-07 / J Clin Oncol 38, 2020 (suppl 5; abstr 63)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-07 / J Clin Oncol 38, 2020 (suppl 5; abstr 63)2020-02-07 00:00:002020-08-31 08:23:53Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis.
https://www.iozk.de/wp-content/uploads/2020/02/Paul-ehrlich-preis2.jpg
350
940
IOZK
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
IOZK2020-02-03 15:40:342023-01-23 16:29:55Ehrung für bahnbrechende Entdeckung in der Immuntherapie für Prof. Shimon Sakaguchi
https://www.iozk.de/wp-content/uploads/2020/01/IOZK-Patienteninformation-Deutsch.jpg
1333
2008
IOZK
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
IOZK2020-02-03 14:21:292020-02-03 14:24:30Die IOZK Patientenbroschüre
